EOLS
Evolus, Inc.
Healthcare — Drug Manufacturers - Specialty & Generic
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
None
6 analysts
$7.69
$-0.31 (-3.87%)
Target:
$14.67
(90.7%)
Price History
52-Week Range
Sign in to add EOLS to a watchlist or set price alerts.
Fundamentals
| Market Cap | $443.86M |
| P/E Ratio (TTM) | - |
| Forward P/E | 28.08 |
| EPS (TTM) | $-0.66 |
| Dividend Yield | - |
| Profit Margin | -14.39% |
| Revenue Growth | 6.70% |
| ROE | - |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | $14.67 |
| Analysts | 6 |
| Next Earnings | Aug 5, 2026 AMC |
| Indexes | - |
Technical Indicators
| RSI (14) | 50.6 |
| Beta | 1.33 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $10.20 |
| 52-Week Low | $3.86 |
| 50-Day Avg | $6.32 |
| 200-Day Avg | $5.89 |
| Avg Volume | 826.2K |
| Volume | 567.6K |
Performance Analysis
NEUTRALEOLS presents a mixed picture with both positive and negative indicators.
~
Trading at 60% of its 52-week range.
~
RSI at 50.6 is in neutral territory.
+
Price is above both the 50-day and 200-day moving averages — strong uptrend.
~
Modest revenue growth of 6.7% year-over-year.
-
Operating at a loss with -14.4% margin.
~
Wall Street consensus is "none" from 6 analysts.
+
Average analyst target of $14.67 implies 90.7% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:08 UTC
Back to Screener Export Report